The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

New research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May) and published in the ...

Patients with diabetes mellitus who use GLP-1 RAs have an increased risk for acute and chronic pancreatitis, according to a study presented at DDW 2025.

Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today an advancement in the use of artificial intelligence (AI) to scale the generation of ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are tied to a reduction in alcohol intake, according to a research ...

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of ...

Researchers used data-driven clustering to define 6 distinct obesity subtypes, offering a potential paradigm shift in how ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

News Evidence That GLP-1 Drugs Achieve Weight Loss Primarily by Reducing Fat Mass More Than Muscle. Diabetes and obesity have become pressing health issues worldwide. Glucagon-lik ...

GLP-1 agonist semaglutide is the active ingredient in Novo Nordisk's blockbuster weight-loss drug Wegovy, which achieved sales of around $8 billion last year. Supply constraints have meant that ...

GLP-1s may help reduce alcohol intake among adults with overweight or obesity, according to data presented at the European ...